10 growth stocks in the S&P 500's bargain sector
The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...
stocknews20h
3 Genomic Stocks at the Forefront of Precision Medicine
Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
Vertex Pharmaceuticals’ (VRTX) Outperform Rating Reiterated at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a research note issued to investors on Friday,RTT News ...
Vertex Pharmaceuticals’ (VRTX) “Hold” Rating Reiterated at Needham & Company LLC
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a report released on Friday,Benzinga reports. A number of other research ...
S&P 500 Gains and Losses Today: UGG Footwear Maker Deckers Outdoor Plunges on Weak Outlook
The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.
FDA approves new, non-opioid painkiller Journavx
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The Tokenist3d
Vertex Pharmaceuticals Stock Soars as Non-Opioid Pain Treatment Gets FDA Nod
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...